BioSpace News Archive

Drug Development

Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 Introducing HADUVIO ™ as Proposed Trade Name for Nalbuphine ER

July 13, 2020
·
5 min read
Business

4Front Announces Fiscal First Quarter 2020 Earnings Date and Conference Call

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”) today announces it plans to issue its fiscal first quarter 2020 earnings press release on Tuesday, July 14, 2020, after U.S. markets close, commensurate with the filing of its unaudited financial results

July 13, 2020
·
4 min read
Genetown

Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran

– Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Will Make Lumasiran Treatment Available for UK Primary Hyperoxaluria Type 1 (PH1) Patients Before Marketing Authorization -- – Lumasiran Indicated Within EAMS for the Treatment of Patients with PH1 --

July 13, 2020
·
11 min read
Biotech Bay

Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress

Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels Data confirm Phase 3 study design to treat acute bleeding events in hemophilia

July 13, 2020
·
5 min read
Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218

July 13, 2020
·
5 min read
Drug Development

Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia

Enzychem Lifesciences (KOSDAQ: 183490) today announced that it has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of EC-18 as a preventative therapeutic against Acute Respiratory Disease Syndrome (ARDS) due to COVID-19 pneumonia. A Phase 2 study for

July 13, 2020
·
3 min read
Tyrosine Kinase Inhibitors Market: VEGFR tyrosine kinase inhibitors is projected to be highly lucrative product segment

The global tyrosine kinase inhibitors market was valued at US$ 18.3 Bn in 2017.

July 13, 2020
·
8 min read
T-cell Acute Lymphoblastic Leukemia Market: Better Government Policies and Initiatives to Contribute in Market Development

Significant players operating in the global T-cell acute lymphoblastic leukemia market incorporate Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Erytech Pharma, Inc., Sanofi, and Celgene Corporation.

July 13, 2020
·
4 min read
Scleroderma Diagnostics and Therapeutics Market: Growing demand for Electrocardiogram to Propel Demand

The demand within the global market for scleroderma diagnostics and therapeutics has been rising on account of advancements in the field of rheumatoid treatments, finds Transparency Market Research.

July 13, 2020
·
4 min read
Recombinant Plasma Protein Therapeutics Market: Rising Number of Regulatory Approvals to Drive Market

Transparency Market Research has published a new report titled, “Recombinant Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

July 13, 2020
·
5 min read